The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Abstract Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy is now another effective treatment op...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ImmunoMedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imed.1039 |